Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -31% Improvement Relative Risk c19early.org/e Monserrat Villatoro et al. Aspirin Prophylaxis Is prophylaxis with aspirin beneficial for COVID-19? PSM retrospective study in Spain Higher mortality with aspirin (p=0.038) Monserrat Villatoro et al., Pharmaceuticals, doi:10.3390/ph15010078 Favors aspirin Favors control
A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis
Monserrat Villatoro et al., Pharmaceuticals, doi:10.3390/ph15010078
Monserrat Villatoro et al., A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of.., Pharmaceuticals, doi:10.3390/ph15010078
Jan 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
PSM retrospective 3,712 hospitalized patients in Spain, showing lower mortality with existing use of azithromycin, bemiparine, budesonide-formoterol fumarate, cefuroxime, colchicine, enoxaparin, ipratropium bromide, loratadine, mepyramine theophylline acetate, oral rehydration salts, and salbutamol sulphate, and higher mortality with acetylsalicylic acid, digoxin, folic acid, mirtazapine, linagliptin, enalapril, atorvastatin, and allopurinol.
risk of death, 31.0% higher, OR 1.31, p = 0.04, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Monserrat Villatoro et al., 8 Jan 2022, retrospective, propensity score matching, Spain, peer-reviewed, 18 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Abstract: pharmaceuticals Article A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis Jaime Monserrat Villatoro 1 , Gina Mejía-Abril 2 , Lucía Díaz García 1 , Pablo Zubiaur 2 , María Jiménez González 3 , Guillermo Fernandez Jimenez 4 , Inés Cancio 4 , José Ramón Arribas 5 , Carmen Suarez Fernández 6 , Jesús Mingorance 7 , Julio García Rodríguez 7 , José Ramón Villagrasa Ferrer 8 , Antonio J. Carcas 1 , Jesús Frías 1 , Francisco Abad-Santos 2, * , Alberto M. Borobia 1, * , Elena Ramírez 1, * and on behalf of the COVID@HULP Working Group and Other Collaborators from Hospital Universitario de la Princesa † 1   2 Citation: Monserrat Villatoro, J.; Mejía-Abril, G.; Díaz García, L.; Zubiaur, P.; Jiménez González, M.; 3 4 Fernandez Jimenez, G.; Cancio, I.; Arribas, J.R.; Suarez Fernández, C.; 5 Mingorance, J.; et al. A Case-Control of Patients with COVID-19 to Explore 6 the Association of Previous Hospitalisation Use of Medication on 7 the Mortality of COVID-19 Disease: A Propensity Score Matching 8 Analysis. Pharmaceuticals 2022, 15, 78. https://doi.org/10.3390/ ph15010078 Academic Editors: Alan J. Hibbitts and Sofia A. Papadimitriou Received: 21 December 2021 Accepted: 4 January 2022 Published: 8 January 2022 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). * † Clinical Pharmacology Department, La Paz University Hospital-IdiPAZ, Universidad Autónoma de Madrid, 28046 Madrid, Spain; jaimemonserratvillatoro@gmail.com (J.M.V.); ldiazg@salud.madrid.org (L.D.G.); antonio.carcas@uam.es (A.J.C.); jesus.frias@uam.es (J.F.) Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), 28006 Madrid, Spain; ginapaola.mejia@salud.madrid.org (G.M.-A.); pablo.zubiaur@salud.madrid.org (P.Z.) Clinical Trial Unit, La Paz University Hospital-IdiPAZ, 28046 Madrid, Spain; jimenezglezmaria@gmail.com Medical Information Unit, Instituto de Investigación Sanitaria La Princesa (IP), Hospital Universitario de La Princesa, 28006 Madrid, Spain; gfjimenez@salud.madrid.org (G.F.J.); Ines.Cancio@dxcfds.com (I.C.) Internal Medicine Department, La Paz University Hospital-IdiPAZ, Universidad Autónoma de Madrid, 28046 Madrid, Spain; joser.arribas@salud.madrid.org Internal Medicine Department, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, 28006 Madrid, Spain; csuarezf@salud.madrid.org Microbiology Department, La Paz University Hospital-IdiPAZ, 28046 Madrid, Spain; jesus.mingorance@idipaz.es (J.M.); jgarciarodriguez@salud.madrid.org (J.G.R.) Preventive Medicine Department, Hospital Universitario de La Princesa, Faculty of Medicine, Instituto de Investigación Sanitaria La Princesa (IP), Universidad Autónoma de Madrid (UAM), 28006 Madrid, Spain; joseramon.villagrasa@salud.madrid.org Correspondence: francisco.abad@uam.es (F.A.-S.); alberto.borobia@salud.madrid.org (A.M.B.); elena.ramirezg@uam.es (E.R.); Tel.: +34-915-202200..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit